Curevac partner gsk announces positive phase 2 data from seasonal influenza mrna vaccine program

Phase 2 data demonstrated positive immune responses to a and b strains, with acceptable safety and reactogenicity profile, meeting all pre-defined study endpoints vaccine candidate based on curevac's proprietary second-generation mrna backbone gsk confirmed data support advancing program to phase 3; dosing of first phase 3 participant is associated with a significant milestone payment for curevac in july 2024, gsk assumed full control for the development, manufacturing and commercialization of influenza vaccines through new licensing agreement tÜbingen, germany and boston, ma / accesswire / september 12, 2024 / curevac n.v. (nasdaq:cvac) ("curevac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mrna"), today announced that gsk has reported positive phase 2 headline data from the seasonal influenza mrna vaccine program.
CVAC Ratings Summary
CVAC Quant Ranking